Deciphera Pharmaceuticals ( DCPH ) announced that it had achieved positive results in a phase 3 study , using its drug ripretinib to treat patients with fourth-line and fifth-line plus gastrointestinal stromal tumors ((GIST)). With these latest results, the biotech holds the potential to ...

Shares of Deciphera Pharmaceuticals (DCPH) have risen by just 1% since my September 2018 article suggested initiating a pilot position in the near term and accumulating weakness. To be fair, I had thought ESMO data for DCC-2618 would boost shares and instead they lost nearly half their value...

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 10,810,810 shares of the Company’s c...